Survey the effect of glasthma in asthma
Phase 2
Recruiting
- Conditions
- asthma.Moderate persistent asthmaJ45.4
- Registration Number
- IRCT20210309050643N2
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Moderate asthma diagnosed by a specialist
Asthma for more than 6 months
FEV1 60-80%
Exclusion Criteria
Cognitive diseases
History of convulsive disease
Using oral or systemic corticosteroids
Pregnancy or breastfeeding
Need to be hospitalized for any reason
Smoking
Exacerbation of the disease at the beginning of the study
Hypertension or diabetes
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in patients' clinical symptoms. Timepoint: At the beginning and 4 weeks after the drug intervention. Method of measurement: International Asthma Registration Questionnaire.;Changes in respiratory test results. Timepoint: At the beginning and 4 weeks after the drug intervention. Method of measurement: Spirometry.;Changes in intestinal permeability. Timepoint: At the beginning and 4 weeks after the drug intervention. Method of measurement: lactolose/manitol ratio in urine.
- Secondary Outcome Measures
Name Time Method Changes in patients' quality of life. Timepoint: First and 4 weeks after drug intervention. Method of measurement: International Asthma Registration Questionnaire.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Glycyrrhiza glabra in Glasthma may influence asthma pathophysiology and intestinal permeability?
How does Glasthma's efficacy in moderate persistent asthma (J45.4) compare to standard bronchodilators or corticosteroids?
Which biomarkers correlate with improved spirometry outcomes in IRCT20210309050643N2 Glasthma trial for asthma patients?
What are the potential adverse events of Glasthma in asthma treatment and how do they compare to placebo in phase II trials?
Are there synergistic effects of combining Glasthma with inhaled corticosteroids in managing asthma-related inflammation and permeability?